How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?

In patients with primary sclerosing cholangitis (PSC), antimicrobial therapy with oral vancomycin (OV) is increasingly used to prevent progression of the liver disease and control concomitant ulcerative colitis (UC); however, there are concerns regarding the risk of development of vancomycin-resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Ayesha, Pakneeshan, Sahar, Jones, Michael P, Koloski, Natasha, Callaghan, Gavin, Morrison, Mark, Holtmann, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715441/
https://www.ncbi.nlm.nih.gov/pubmed/36217097
http://dx.doi.org/10.1007/s12664-022-01286-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715441/
https://www.ncbi.nlm.nih.gov/pubmed/36217097
http://dx.doi.org/10.1007/s12664-022-01286-9

Ejemplares similares